Childhood Cancer May Start When Immunity Attacks DNA Repair

Some children who develop cancer may carry a clue in their blood years before a diagnosis: antibodies that attack the very proteins their cells use to repair damaged DNA. A Norwegian research team reports that children with cancer were far more likely than healthy peers to carry these self-directed antibodies, and that the signal showed up in stored blood samples taken years before illness appeared.

The finding points to a previously unsuspected route into childhood cancer. Most cancers in adults build up over decades of exposure and accumulated genetic damage. Childhood cancers look different: they tend to carry fewer mutations and arise from younger, less mature cells. That contrast has long left researchers asking what tips a young cell toward childhood cancer when it has had so little time to collect damage. The new work offers a candidate answer, according to the study team: the immune system itself may be disabling the repair machinery that keeps young cells safe.

The immune system turned on its own repair crew

Every cell carries a repair crew of hundreds of proteins that spot and fix damage or errors in the genome. When that crew works, routine damage gets patched before it can turn dangerous. When it falters, mutations pile up and cancer risk rises. Inherited defects in repair genes are already known to raise cancer risk in some families. Earlier coverage of inherited cancer risk has examined why older gene tests sometimes miss dangerous variants. The new study suggests the immune system can create a similar weakness from the outside, by producing antibodies that bind and block repair proteins.

The researchers examined tumor and blood samples from 175 adults and children with sarcoma or acute lymphoblastic leukemia, gathered between 2014 and 2017 through Norwegian biobanks. They compared those samples with blood from healthy donors and from children in a Bergen growth study, then looked for antibodies aimed at DNA repair proteins. Children between two and 19 years old with cancer carried far more of these antibodies, of the IgG class, than young adults or older people. The antibodies concentrated on six proteins central to genome maintenance: RAD52, NUMA1, ALKBH7, APBB1, UNG and MGMT. None of those genes was significantly mutated in the cancers studied, which means the proteins themselves looked intact, yet the immune system appeared to be working against them.

Lab experiments then showed how that attack could do real harm. The antibodies were able to enter living cells, especially as cells prepared to divide, and home in on a structure called the TIGER domain, where short-lived proteins get made and modified. Once inside, they could latch onto their targets and slow or block repair. As the authors put it, the results together provide a plausible mechanism for increased cellular damage that could lead to cancer development.

A warning signal for childhood cancer years before diagnosis

The most striking part of the study came from looking backward in time. The team analyzed stored samples from 59 school-age children who had taken part in two long-running British cohort studies. About half of those children went on to develop cancer before the age of 30, while the rest stayed healthy. Because the blood had been drawn years earlier, the researchers could ask whether the antibody signal predated the disease.

It did. Children who later developed cancer, on average six years after their blood was sampled, were about eight times more likely than their healthy peers to carry antibodies against at least one core repair protein. That timing matters: it suggests the antibodies are not merely a consequence of cancer or its treatment, but a possible early footprint of the disease process itself. The team cautions that the cohort was small, and corresponding author Ola Myklebost of the Bergen university described it as the best sample the group could find internationally for this purpose. Still, the association held up strongly enough to warrant a closer look.

The researchers also offered early ideas about what might trigger the misdirected antibodies. Infections, cross-reactions with microbial proteins, overstimulation of the immune response, or a breakdown in immune tolerance could all play a role, Myklebost said. None of those triggers is proven yet, and untangling them will take more work.

What it could mean, and what it does not prove yet

If the finding holds in larger studies, it could open a path to screening young children for an autoimmune predisposition to childhood cancer, catching risk early enough to watch for disease or, one day, to intervene. That prospect is what makes the study matter beyond the laboratory: childhood cancer is rare, but when childhood cancer strikes, families face gruelling treatment and lifelong follow-up. A blood test that flags risk before symptoms appear would change how doctors monitor vulnerable children.

For now, the researchers stress that no such test exists, and the work is a first step rather than a clinical tool. The association needs confirming in bigger groups, and the team still has to show that patient antibodies can cripple repair in living cells and drive cancer in animals. Those experiments are already under way, with tests on induced mutations in cultured cells and plans to study antibody-secreting white blood cells in mice.

There is also a counterpoint worth keeping in view. Autoantibodies are common, and many people carry them without ever getting sick, so the presence of these antibodies alone may never be enough to predict any one child's future. The Bergen team frames the result as evidence for a new mechanism behind childhood cancer, not a verdict on any individual case. What it does change is the list of suspects in childhood cancer: alongside inherited mutations and environmental exposures, the immune system's own friendly fire now has a place in the picture. Recent work mapping how repair proteins assemble has shown how specific mutations weaken the system. The study was published in a peer-reviewed immunology journal, as reported by the journal's announcement, and the team says the next phase will test whether blocking or removing these antibodies can restore repair and lower childhood cancer risk.